Lakefront Biotherapeutics (LKFT) Net Income (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Income for 13 consecutive years, with $709471.9 the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income fell 41.35% year-over-year to $709471.9; the TTM figure through Mar 2026 stood at $1.0 million (down 90.03% YoY), while the FY2025 annual figure was $1.6 million, down 97.99% from the prior year.
• Net Income advanced to $709471.9 in Q1 2026 per LKFT's latest filing, from -$399266.9 in the prior quarter.
• Across five years, Net Income topped out at $212.8 million in Q4 2023 and bottomed at -$80.6 million in Q2 2022.
• Historically, Net Income has averaged $7.0 million across 5 years, with a median of $709471.9 in 2026.
• Annual changes were most pronounced in 2022 — Net Income plunged 2066.43% — and 2023, when it surged 433.61%.
• Lakefront Biotherapeutics' Net Income stood at -$68.5 million in 2022, then jumped by 410.84% to $212.8 million in 2023, then plunged by 96.89% to $6.6 million in 2024, then plunged by 106.04% to -$399266.9 in 2025, then soared by 277.69% to $709471.9 in 2026.
• Business Quant data shows LKFT's Net Income at $709471.9 in Q1 2026, -$399266.9 in Q4 2025, and $2.1 million in Q3 2025.